A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 301–400 of 1,003
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., et al. (2026) · Cell · doi:10.1016/j.cell.2026.02.001 · Cited by 32
Targeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 23
“37–41”
Ozkaya, E., Kennedy, P., Chen, J., Bane, O., Dillman, J. R., Jhaveri, K. S., Ohliger, M. A., Rossman, P. J., Tkach, J. A., Doucette, J. T., et al. (2024) · Radiology · doi:10.1148/radiol.233136 · Cited by 21
Takeuchi, K., Yamaguchi, K., Takahashi, Y., Yano, K., Okishio, S., Ishiba, H., Tochiki, N., Kataoka, S., Fujii, H., Iwai, N., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-75107-8 · Cited by 25
“Wild-type mouse Gdf15 and Fgf21 cDNA constructs obtained by PCR amplification were subcloned into the pLIVE vector (Mirus Bio, Madison, WI, USA), and the pLIVE vectors expressing mouse Gdf15 or Fgf21 were delivered via hydrodynamic tail vein injection 7 .”
Galectin-3 in metabolic disorders: mechanisms and therapeutic potential
Jiang, Q., Zhao, Q., & Li, P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.11.006 · Cited by 23
Ciociola, E., Dutta, T., Sasidharan, K., Kovooru, L., Noto, F. R., Pennisi, G., Petta, S., Mirarchi, A., Maurotti, S., Scopacasa, B., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0642 · Cited by 27
Brennan, P., Kopka, C. J., Agirre‐Garrido, L., Hansen, C. D., Alkhouri, N., Schattenberg, J. M., Wajcman, D. I., Isaacs, S. D., Michel, M. S., & Lazarus, J. V. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00017-5 · Cited by 25
“7 .”
InfluentialSelf-citationBoulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
Liver and obesity: a narrative review
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001334 · Cited by 23
Bharaj, I. S., Brar, A. S., Kahlon, J., Singh, A., Hotwani, P., Kumar, V., Sohal, A., & Batta, A. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i6.106147 · Cited by 19
Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver Disease
Le, P. N. B., Dasarathy, S., Herman, W. H., Adekunle, O. A., Tran, H. T., Criswell, V., Ye, W., Welch, N., Yue, Y., & Rothberg, M. B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17122 · Cited by 23
Screening for advanced steatotic liver disease
Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 20
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 27
Radu, F. I., Patoni, C., Nancoff, A.-S., Marin, F.-S., Gaman, L. E., Bucurica, A., Socol, C., Jinga, M., Duţu, M., & Bucurica, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084201 · Cited by 21
“The most recently approved molecule for NASH treatment is Resmetirom, a thyroid hormone receptor beta (THR-β ) selective agonist, with per os administration [59,60].”
BackgroundJiang, F.-Y., Yue, S., Tan, Y.-Y., Tang, N., Xu, Y., Zhang, B., Mao, Y.-J., Xue, Z., Lü, A., Liu, B., et al. (2024) · Nutrients · doi:10.3390/nu16111782 · Cited by 20
“In March 2024, the FDA approved the first innovative drug, which aimed at adult patients with NASH accompanied by liver fibrosis [5].”
BackgroundGurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Martins, M. C., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2024) · Liver International · doi:10.1111/liv.16117 · Cited by 28
Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials
Fichez, J., Mouillot, T., Vonghia, L., Costentin, C. E., Moreau, C., Roux, M., Delamarre, A., Francque, S., Zheng, M., & Boursier, J. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101351 · Cited by 21
Self-citationTherapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Alkhouri, N., Yip, T. C., Castéra, L., Takawy, M., Adams, L. A., Verma, N., Arab, J. P., Jafri, S., Zhong, B., Dubourg, J., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003432 · Cited by 33
Self-citationZhong, J., Cai, Z., Zhu, G., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16348 · Cited by 18
Queathem, E. D., Stagg, D. B., Nelson, A. B., Chaves, A., Crown, S. B., Fulghum, K., d’Avignon, D. A., Ryder, J. R., Bolan, P. J., Hayir, A., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191021 · Cited by 27
“…FDA-approved drug available for the treatment of MASLD-MASH, while several others have failed owing to poor efficacy and/or toxicity, illustrating a need to understand the drivers of hepatic fat accumulation and its mechanistic link to the development of injury and advanced liver disease (7, 8).”
Díaz, L. A., Tavaglione, F., Mittal, N., Bettencourt, R., Amangurbanova, M., Johnson, A., Aguado, D. M., Tincopa, M. A., Loomba, R. K., Khan-Riches, A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000718 · Cited by 25
“In the entire cohort, the median alcohol intake was 77 [32 – 161] g/wk, while the median AUDIT scores were 5 [3 – 9], and the median PEth levels were 79 [41 – 200] ng/mL.”
Self-citationMetabolic and Functional Cross Talk Between the Thyroid and Liver
Chng, C. L., Goh, G. B., & Yen, P. M. (2025) · Thyroid · doi:10.1089/thy.2025.0178 · Cited by 38
Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights
Zhu, C.-Y., Yu, P., Sun, Q., Hong, D., Yang, C., & Naranmandura, H. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107862 · Cited by 19
Younossi, Z. M., Paik, J. M., Lazarus, J. V., Burra, P., Eguchi, Y., Tacke, F., Crespo, J., Villela‐Nogueira, C. A., Brennan, P., Al‐Omar, H. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.002 · Cited by 35
Self-citationZonation, Zonation, Zonation: The Real Estate of the Liver
Yasaka, T. M., Kim, C., Meadows, V., & Monga, S. P. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-042624-091820 · Cited by 30
From steatosis to cirrhosis: the role of obesity in the progression of liver disease
Nowak, K., Paluch, M., Cudzik, M., Syska, K., Gawlikowska, W., & Janczura, J. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01754-x · Cited by 21
“These findings confirmed that both doses of resmetirom were significantly more effective than placebo in achieving NASH resolution and improving liver fibrosis by at least one stage [48 ].”
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 28
“186 Based on these phase 3 outcomes, the U.S. Food and Drug Administration has recently approved resmetirom for the treat-ment of noncirrhotic MASH.”
Gao, Y., Li, C., Chang, W., Du, B., Ye, X., Yeo, Y. H., Xia, Y., Guo, H., Zhang, X., Liu, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68414-3 · Cited by 31
Cheu, J. W., & Wong, C. C. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000516 · Cited by 25
“[20] Although resmetirom is expected to prevent MASH-HCC, more experimental and clinical evidence is needed.”
BackgroundTargeting acetyl-CoA carboxylases for the treatment of MASLD
Mateo-Marín, M. A., & Alves‐Bezerra, M. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100676 · Cited by 28
Management strategies for metabolic dysfunction–associated steatotic liver disease (MASLD)
Alkhouri, N., & Noureddin, M. (2024) · The American Journal of Managed Care · doi:10.37765/ajmc.2024.89635 · Cited by 29
Self-citationCaffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9
Xin, X., Chen, C., Xu, X., Lv, S., Sun, Q., An, Z., Chen, Y., Xiong, Z., Hu, Y., & Feng, Q. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103499 · Cited by 21
“Recently, resmetirom (rezdiffra) was approved by the U.S. Food and Drug Administration for treating adults with noncirrhotic MASH with moderate to advanced liver scar-ring (fibrosis), to be used alongside diet and exercise [38 – 40].”
Sharma, S., Tiwari, N., & Tanwar, S. S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04069-z · Cited by 35
PPARα-ERRα crosstalk mitigates metabolic dysfunction-associated steatotic liver disease progression
Antwi, M. B., Lefere, S., Clarisse, D., Koorneef, L. L., Heldens, A., Onghena, L., Decroix, K., Fijałkowska, D., Thommis, J., Hellemans, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156128 · Cited by 22
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 25
“Recently, the selective thyroid hormone receptor β (THR-β ) agonists have been found to be effective in the treatment of MAFLD [72,73], and approved by FDA.”
Call to action—Pediatric MASLD requires immediate attention to curb health crisis
Hartmann, P., Mouzaki, M., Hassan, S. M., Kehar, M., Mysore, K. R., Mauney, E. E., Nonga, D., Karjoo, S., Sood, S., Tou, A. M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001440 · Cited by 20
Self-citationThe autophagy-senescence axis as a threshold model of aging and therapeutic targeting
Bahar, M. E., Hwang, J. S., Lai, T. H., Akter, K.-M., Maulidi, R. F., & Kim, D. R. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104079 · Cited by 25
“Mechanistically, THR-β activation enhances mitochondrial function and stimulates autophagy and mitophagy pathways in hepatocytes, thereby reducing lipotoxic stress and preventing transition into a post-threshold senescent state [63].”
Chen, L., Horn, P., & Tacke, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70545 · Cited by 23
Hallmarks of liver cancer: Therapeutic implications
Llovet, J. M., Pinyol, R., Affò, S., Yarchoan, M. M., Gores, G. J., Kelley, R. K., Lowe, S. W., Sia, D., & Villanueva, A. (2026) · Cell · doi:10.1016/j.cell.2026.03.001 · Cited by 23
“69,70 While their impact on HCC development remains unknown, their ability to address fibrosis—one of the strongest predictors of HCC—presents a promising opportunity for HCC prevention.”
Implementing sustainable liver health in Europe: a second EASL–Lancet Commission
Karlsen, T. H., Hutchinson, S. J., Zelber‐Sagi, S., Carrieri, P., Negro, F., Lim, A. G., Cecchini, M., Dirac, M. A., Murray, F., Engebretsen, E., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00138-8 · Cited by 21
Self-citationNuclear receptors: pathophysiological mechanisms and drug targets in liver disease
Dubois, V., Lefèbvre, P., Staels, B., & Eeckhoute, J. (2024) · Gut · doi:10.1136/gutjnl-2023-331741 · Cited by 18
“75 Thus, resmetirom became very recently the first FDA-approved treatment for MASH.”
Li, Y., Chen, L., Sottas, C. M., Raul, M. C., Patel, N. D., Bijja, J. R., Ahmed, S. K., Kapelanski‐Lamoureux, A., Lazaris, A., Metrakos, P. P., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155942 · Cited by 22
Jiménez, V., Sacristan, V., Jambrina, C., Jaén, M. L., Casana, E., MUÑOZ, S. A., Marcó, S., Molas, M., García, M., Grass, I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.023 · Cited by 16
Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16874 · Cited by 20
“[93].”
Mathur, A., Ozkaya, E., Rosberger, S., Sigel, K. M., Doucette, J. T., Bansal, M. B., & Taouli, B. A. (2025) · European Radiology · doi:10.1007/s00330-025-11533-0 · Cited by 18
Self-citationIncremental Value of Blood-Based Markers of Liver Fibrosis in Cardiovascular Risk Stratification
Georgiopoulos, G. A., Athanasopoulos, S., Mavraganis, G., Konstantaki, C., Papaioannou, M., Delialis, D., Angelidakis, L., Sachse, M., Papoutsis, D., Cavlan, B., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae619 · Cited by 22
Yu, P., Yuan, H., Li, X., & Chen, H. (2024) · Endocrine · doi:10.1007/s12020-024-04043-4 · Cited by 18
Weng, M., Yang, P., Liu, P.-F., Chang, C.-H., Lee, M., Sheu, J., & Nien, H. (2024) · Hepatology International · doi:10.1007/s12072-024-10758-3 · Cited by 17
“Resmetirom is the first FDA-approved medication for treating nonalcoholic steatohepatitis (NASH) [6].”
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
Pu, S., Zhao, B., Jiang, Y., & Cui, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02474-0 · Cited by 27
“Furthermore, liver enzyme levels also decreased more significantly in the Resmetirom group compared to the placebo group [92].”
InfluentialAllo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis
Marchianò, S., Biagioli, M., Giorgio, C. D., Massa, C., Bellini, R., Bordoni, M., Urbani, G., Lachi, G., Sepe, V., Morretta, E., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116883 · Cited by 18
Panagiotopoulos, N., Wolfson, T. J., Harris, D. T., Batakis, D., Agni, R. M., Ceriani, L., Covarrubias, Y., Hamilton, G., Middleton, M. S., Martins, V. F., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001318 · Cited by 20
He, L., She, X., Guo, L., Gao, M., Wang, S., Lu, Z., Guo, H.-T., Li, R., Nie, Y., Xing, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58790-7 · Cited by 21
Lin, Y., Liao, F., Chao, H., Chen, A., Jeng, Y., Lin, C., Tiao, M., Yang, Y., Yeung, C., Chen, H., et al. (2025) · JGH Open · doi:10.1002/jgh3.70137 · Cited by 20
“Adults with biopsy-confirmed MASH and a fibrosis stage of F1B, F2, or F3 showed both MASH resolution and fibrosis improvement after 52 weeks of resmeti-rom treatment [79].”
Shantaram, D., Rima, X. Y., Bradley, D. P., Liu, J. Z., Wright, V. P., AMARI, A., Jalilvand, A., Rottinghaus, J., Fernandes, J. M., Smith, A. J., et al. (2025) · Diabetes · doi:10.2337/db24-0861 · Cited by 18
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders
Dobre, M.-Z., Vîrgolici, B., & Cioarca-Nedelcu, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070565 · Cited by 23
“Trial adherence and tolerability are optimized through close monitoring, unlike real-world settings where gastro-intestinal side effects and fasting requirements may reduce compliance [148].”
Giannakogeorgou, A., Roden, M., & Pafili, K. (2025) · HORMONES · doi:10.1007/s42000-025-00701-y · Cited by 24
Huber, Y., Hofmann, L. J., Prochaska, J. H., Koeck, T., Chalabi, J., Pfeiffer, N., Beutel, M. E., Strauch, K., Lackner, K. J., Tuescher, O., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70053 · Cited by 19
“70,7 1 With the emergence of these therapies, screening tools to identify individuals with advanced hepatic fibrosis related to MASLD are implemented.”
Self-citationTamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
“Notably, the improvements in liver enzyme observed in this analysis (SMD for ALT: −0.47) are comparable to those reported in dedicated MAFLD? trials with other therapeutic agents but were achieved in a broader MAFLD population, including patients without biopsy-confirmed steatohepatitis [62, 63].”
InfluentialIs liver steatosis a disease or the emperor’s new clothes?
Krag, A. A., Tacke, F., Israelsen, M. E., & Younossi, Z. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.12.026 · Cited by 18
Self-citationKaplan, L. M., Startseva, E., le Roux, C. W., Wharton, S., Bozkurt, B., Mazo, D. F. D. C., von Schlippenbach, J., Maldonado, S. G., Hussain, S. A., Neff, G. W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04479-3 · Cited by 29
“…peptide-1 receptor (GLP-1R) agonist activity (semaglutide and tirze-patide) 15,16 and medications that are conditionally approved by the US Food and Drug Administration for the treatment of MASH with moderate-to-advanced liver fibrosis (stage F2/F3; semaglutide and res-metirom) 5,15,17–19 .”
Self-citationWhite adipose tissue in metabolic associated fatty liver disease
Zhu, X., Zeng, C., & Yu, B. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102336 · Cited by 18
Raja, A., Sagar, R. S., Saeed, S., Haq, A., Khan, O., Bhimani, P. D., Raja, S., Deepak, F., Ahmed, M., Shafique, M. A., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002195 · Cited by 18
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Khaznadar, F., Khaznadar, O., Petrovic, A., Hefer, M., Gjoni, F., Gjoni, S., Steiner, J., Smolić, M., & Bojanić, K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070376 · Cited by 23
“[38,39].”
ResultYeh, M., Huang, J., Dai, C., Huang, C., Yu, M., & Chuang, W. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2388790 · Cited by 16
“Recently, the U.S. FDA approved the first treatment for adults with NASH and moderate to advanced liver fibrosis: a thyroid hormone receptor beta-selective agonist [70].”
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107375 · Cited by 16
Luo, S., Zheng, M., Wong, V. W., & Yeung, S. L. A. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100114 · Cited by 19
Rapacciuolo, P., Finamore, C., Giorgio, C. D., Fiorillo, B., Massa, C., Urbani, G., Marchianò, S., Bordoni, M., Cassiano, C., Morretta, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01651 · Cited by 17
Reprogramming macrophages to treat liver diseases
Simón-Codina, B., Cacho-Pujol, J., Moles, A., & Melgar‐Lesmes, P. (2024) · Hepatology · doi:10.1097/hep.0000000000001160 · Cited by 22
“Resmetirom : [83] Approved by FDA.”
Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics
Flam, E. L., Haas, J. T., & Staels, B. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119054 · Cited by 19
Gurjar, S., Ramanarayana Bhat, A., Upadhya, R., & Shenoy, R. P. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02396-3 · Cited by 21
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 19
“…), and downregulating sterol regulatory element-binding protein 1c ( SREBP-1c ), resmetirom effectively decreases hepatic triglyceride accumulation [15,28–30 ,32– Resmetirom, when administered in doses of 80 mg and 100 mg per day, has demonstrated a significant positive impact on liver health,…”
InfluentialBeyer, C., Andersson, A., Shumbayawonda, E., Alkhouri, N., Banerjee, A., Pandya, P., Harisinghani, M. G., Corey, K. E., Dennis, A., & Pansini, M. (2024) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.29610 · Cited by 19
Self-citationVisser, A., Hussain, M. M., & Kuivenhoven, J. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000983 · Cited by 21
Cheung, J., Cheung, B. M. Y., Yiu, K., Tse, H., & Chan, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1573841 · Cited by 18
A Real-World Experience With Resmetirom: Tolerability and Access
Shuaibi, S. N., Tobal, I., Gore, J., Ebiai, R., Ozoral, C., & Therapondos, G. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100709 · Cited by 17
Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective
Miedel, M. T., Schurdak, M. E., Stern, A. M., Soto–Gutiérrez, A., Strobl, E. V., Behari, J., & Taylor, D. L. (2025) · Seminars in Liver Disease · doi:10.1055/a-2649-1560 · Cited by 23
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H. R., Dahiya, D. S., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 23
“This dual action improves hepatic steatosis, inflammation, and fibrosis, as demonstrated in clinical trials [31].”
InfluentialTargeting ferroptosis to halt MASLD and MASH
Wang, F. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2026.01.007 · Cited by 18
Resmetirom proves positive for NASH with liver fibrosis
Ray, K. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00909-0 · Cited by 15
Mantri, A., Köhlmoos, A., Schelski, D. S., Seel, W., Stoffel‐Wagner, B., Krawitz, P. M., Stehle, P., Holst, J. J., Weber, B., Koban, L., et al. (2024) · Nutrients · doi:10.3390/nu16091300 · Cited by 17
“Only recently, a study [45] found that resmetirom improved fibrosis in 966 patients with NASH and fibrosis of stage F1B, F2, or F3.”
BackgroundResmetirom for MASH patients with diabetes: challenges and opportunities in the real world
Lian, L., Targher, G., Byrne, C. D., Liu, W., & Zheng, M. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155935 · Cited by 15
Kalopitas, G., Arvanitakis, K., Tsachouridou, Ο., Malandris, K., Koufakis, T., Metallidis, S., & Germanidis, G. S. (2024) · Life · doi:10.3390/life14060742 · Cited by 15
“…with the help of lifestyle modifications and medications according to clinical practice guidelines, while newer effective pharmaceutical agents will soon be available for the management of MASLD/NAFLD, as resmetirom has recently been officially approved for the treatment of steatohepatitis [59].”
BackgroundInterplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Lee, N. Y., Choi, M. G., Lee, E. J., & Koo, J. H. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01501-5 · Cited by 20
“It is indicated for use only in relatively mild cases of the F2 stage fibrosis which have not yet progressed to cirrhosis, suggesting that there remains a vast and unmet clinical need (Harrison et al. 2024).”
BackgroundTrusz, G. J. (2024) · Differentiation · doi:10.1016/j.diff.2024.100793 · Cited by 15
Chang, K., Kuo, F.-C., Yang, C., Yang, C.-T., Ou, H., & Kuo, S. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02461-2 · Cited by 20
“Although the U.S. Food and Drug Administration recently approved resmetirom for the treatment of adults with noncirrhotic NASH [5], lifestyle modification or alone, including smoking cessation, diet control, weight management, and exercise, remains essential [6–8].”
BackgroundHuang, J., Chang, T., Yeh, M., Shen, F., Tai, C., Chen, J., Huang, Y., Hsu, C., Cheng, P., Lin, C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000571 · Cited by 17
“[106] Meanwhile, > 20 drugs are being investigated.”
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 20
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease
Dale, K., Fallouh, Y., & Alkhouri, N. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2401907 · Cited by 16
“New therapeutic options are becoming available in the hepatology clinic with the historic FDA approval of the first drug for MASH, resmetirom, in March of 2024 [8,9].”
Self-citationYan, R., & Cao, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13010206 · Cited by 21
“The therapeutic efficacy of Rezdiffra treatment is also limited, with only ~30% of patients presenting with improved NASH symptoms [15].”
Carabrone Attenuates Metabolic Dysfunction–Associated Steatohepatitis by Targeting STAT3 in Mice
Pan, A., Jin, J., Wu, Y., Zhang, Q., Chen, H., Hu, Y., Xiao, W., Shi, A., Yang, Y., Jiang, L., et al. (2025) · MedComm · doi:10.1002/mco2.70145 · Cited by 15
“Only one new drug, resmetirom, was approved by the FDA in 2024 [7].”
Detecting at-risk steatotic liver disease and liver fibrosis in the community
Adams, L. A., Thiele, M. S., & Tsochatzis, E. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001400 · Cited by 15
Browne, S., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Georges, B., Roberts, M. S., & Harris, M. S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101483 · Cited by 18
Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081118 · Cited by 22
“…been investigated, including vitamin E, pioglitazone, and obeticholic acid, until recently, only resmetirom had received regulatory approval specifically for MASLD treatment, being granted accelerated FDA approval in March 2024 for noncirrhotic MASH with moderate to advanced liver fibrosis [11,12].”
Ratziu, V., Surabattula, R., Bugianesi, E., Schattenberg, J. M., Myneni, S. R., Rosso, C., Armandi, A., Pais, R., Kara, L., Charlotte, F., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335598 · Cited by 15
“6 These data provide clinical relevance to the body of mechanistic evidence linking TSP2 to fibrogenesis and fibrosis accumulation as well as to mechanisms of hepatic inflammation.”
Self-citationShen, S., Liu, Y., Wang, N., Huang, Z., & Deng, G. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1621583 · Cited by 18
Goodheart, R. H., & Ayonrinde, O. T. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.009 · Cited by 21
Zhang, C., Shi, J., & Shi, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1696506 · Cited by 17
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.